Article

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

2019-06-21

Abstract excerpt

Many drugs are promiscuous and bind to multiple targets. On the one hand, these targets may be linked to unwanted side effects, but on the other, they may achieve a combined desired effect (polypharmacology) or represent multiple diseases (drug repositioning). With the growth of 3D structures of drug-target complexes, it is today possible to study drug promiscuity at the structural level and to screen vast amounts...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3ccdae9-91ac-5a66-a1e7-06da72b9b6e5
DOI: 10.1101/678896

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitorDOI 10.1101/678896Read

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and functionSemantic proximity Read

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligandsSemantic proximity Read

The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against CancerSemantic proximity Read

A comprehensive map of molecular drug targets.Semantic proximity Read

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read

Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems PharmacologySemantic proximity Read

Repurposing of Drugs in Autoimmune Diseases: From Serendipity to System ResetSemantic proximity Read

Virtual Screening and Identification of Non-covalent Reversible Small-molecule BTK Inhibitors from a Library of Known Bioactive CompoundsSemantic proximity Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

Bebtelovimab-bound SARS-CoV-2 RBD mutants: resistance profiling and validation with escape mutations, clinical results, and viral genome sequences.Semantic proximity Read

From identification of the BTK kinase to effective management of leukemiaSemantic proximity Read